Sanofi US
270 Albany Street
Cambridge
Massachusetts
02139
United States
Tel: 800-446-6267
Website: http://www.sanofi.us/
About Sanofi US
Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With more than 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, employs more than 17,000 professionals throughout the country. At Sanofi, we work for what really matters: Health.
143 articles with Sanofi US
-
FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
5/20/2022
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg.
-
Sanofi, AstraZeneca, Avillion and Diadem recently announced clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.
-
AstraZeneca and Sanofi’s Phase-III and Phase-IIb clinical trials investigating the efficacy of nirsevimab shows 79.5% efficacy in the prevention of lower respiratory tract infections.
-
IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi$150 Million Payment to IGM from Sanofi
5/6/2022
IGM Biosciences, Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the HSR Act), has expired in connection with the Company’s previously announced exclusive worldwide collaboration agreement with Sanofi.
-
Oxford, UK-based OMass Therapeutics closed on a $100 million Series B financing round. The round was led by new investors GV (formerly Google Ventures), Northpond Ventures and Sanofi Ventures. Three existing investors also participated: Syncona, Oxford Science Enterprise and Oxford University.
-
In its 2022 Q1 earnings report, Sanofi reported major wins in the first quarter of 2022, driven mostly by the success of consumer healthcare (CHC) and Dupixent.
-
AbbVie and Genmab announced positive topline results from their Phase I/II trial for lymphoma treatment; Sanofi posted positive results from its Phase I/II trial for the treatment of ITP.
-
Sempre Health Improved Medication Adherence by 25% for Diabetes Patients Prescribed Sanofi Medications
4/13/2022
Collaboration Supports Companies' Joint Focus on Medication Adherence and Affordability.
-
Eli Lilly has shared positive results of lebrikizumab combination therapy with topical corticosteroids, which is intended to treat atopic dermatitis (AD).
-
Six months after acquiring Kadmon Holdings, pharma giant Sanofi is closing Kadmon’s New York facility. As part of the paring down, Sanofi is also laying off 25 employees at the location.
-
Money on the Move: March 23-29
3/30/2022
This week, money moved in the form of equity financing, upfront partnership payments, nonprofit donations and federal funding. -
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
3/26/2022
Detailed positive results from the Phase 3 PRIME2 trial evaluating the safety and efficacy of Dupixent® was presented in a late-breaking session at the American Academy of Dermatology 2022 Annual Meeting.
-
Read on to learn more about three Series B and C financing rounds in the areas of genetically encoded small molecules, artificial intelligence (AI) and immuno-oncology (IO).
-
Prellis Biologics Announces Collaboration with Sanofi
3/22/2022
Prellis Biologics, Inc. (Prellis), a Bay Area biotherapeutics company, announced today that it has entered into a collaboration and license option agreement with Sanofi S.A. focused on the discovery of antibodies with Prellis’ first-in-class external human immune system (EXIS™).
-
Healthcare giant Sanofi and cancer-focused biotech company Seagen Inc. announced an exclusive collaboration agreement to develop antibody-drug conjugates (ADCs) for cancer treatments.
-
Cambridge Crossing will enable innovative drug discovery platforms for chemistry, protein engineering, structural and synthetic biology, among other key modalities.
-
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
-
Sanofi, AstraZeneca Express Optimism Over Phase III Infant Respiratory Syncytial Virus Results
3/3/2022
In the Phase III MELODY trial, researchers found a 74.5% lower incidence of respiratory syncytial virus-caused pneumonia, and bronchiolitis. Here's more about it. -
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates
3/2/2022
Adagene Inc. announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi.
-
In 2021, Sanofi earned about $4.2 billion from Dupixent sales, and Regeneron earned about $1.8 billion.